Ras farnesyltransferase: a new therapeutic target.
Leonard
D M
DM
Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Company, Ann Arbor, Michigan 48105, USA.
D019883:Alkyl and Aryl Transferases; D000595:Amino Acid Sequence; D000818:Animals; D017871:Calcium-Calmodulin-Dependent Protein Kinases / Q000378:metabolism; D015195:Drug Design; D004791:Enzyme Inhibitors / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D011905:Genes, ras; D006133:Growth Substances / Q000502:physiology; D006801:Humans; D008969:Molecular Sequence Data; D009154:Mutation; D009369:Neoplasms / Q000235:genetics; D017368:Protein Prenylation; D016283:Proto-Oncogene Proteins p21(ras) / Q000235:genetics / Q000378:metabolism; D015398:Signal Transduction; D014166:Transferases / Q000037:antagonists & inhibitors / Q000378:metabolism*; D018631:ras Proteins / Q000737:chemistry / Q000378:metabolism*
D004791:Enzyme Inhibitors; D006133:Growth Substances; D014166:Transferases; D019883:Alkyl and Aryl Transferases; C064911:p21(ras) farnesyl-protein transferase; D017871:Calcium-Calmodulin-Dependent Protein Kinases; C501009:HRAS protein, human; D016283:Proto-Oncogene Proteins p21(ras); D018631:ras Proteins